230 related articles for article (PubMed ID: 30024813)
1. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Booth L; Roberts J; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
[TBL] [Abstract][Full Text] [Related]
2. Valproate augments Niraparib killing of tumor cells.
Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
[TBL] [Abstract][Full Text] [Related]
3. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
Mitchell C; Park M; Eulitt P; Yang C; Yacoub A; Dent P
Mol Pharmacol; 2010 Nov; 78(5):909-17. PubMed ID: 20696794
[TBL] [Abstract][Full Text] [Related]
5. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
6. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
Booth L; Cruickshanks N; Ridder T; Dai Y; Grant S; Dent P
Cancer Biol Ther; 2013 May; 14(5):458-65. PubMed ID: 23917378
[TBL] [Abstract][Full Text] [Related]
7. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Tang Y; Hamed HA; Poklepovic A; Dai Y; Grant S; Dent P
Mol Pharmacol; 2012 Aug; 82(2):322-32. PubMed ID: 22596349
[TBL] [Abstract][Full Text] [Related]
9. CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells.
Rogers RF; Walton MI; Cherry DL; Collins I; Clarke PA; Garrett MD; Workman P
Cancer Res; 2020 Apr; 80(8):1735-1747. PubMed ID: 32161100
[TBL] [Abstract][Full Text] [Related]
10. GZ17-6.02 and axitinib interact to kill renal carcinoma cells.
Booth L; West C; Moore RP; Hoff DV; Dent P
Oncotarget; 2022; 13():281-290. PubMed ID: 35136485
[TBL] [Abstract][Full Text] [Related]
11. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
12. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.
Roberts JL; Poklepovic A; Booth L; Dent P
Cell Signal; 2020 Jun; 70():109573. PubMed ID: 32087304
[TBL] [Abstract][Full Text] [Related]
13. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
14. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.
Booth L; Roberts JL; Poklepovic A; Gordon S; Dent P
Oncotarget; 2017 Jan; 8(1):1449-1468. PubMed ID: 27903966
[TBL] [Abstract][Full Text] [Related]
15. Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma.
Ji Y; Wang Q; Zhao Q; Zhao S; Li L; Sun G; Ye L
Appl Microbiol Biotechnol; 2019 Dec; 103(23-24):9557-9568. PubMed ID: 31686145
[TBL] [Abstract][Full Text] [Related]
16. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
Dent P; Booth L; Poklepovic A; Kirkwood JM
Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
[TBL] [Abstract][Full Text] [Related]
17. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
18. Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells.
Roberts JL; Booth L; Poklepovic A; Dent P
Front Oncol; 2021; 11():723966. PubMed ID: 34604061
[TBL] [Abstract][Full Text] [Related]
19. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
20. Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
Booth L; Cruickshanks N; Tavallai S; Roberts JL; Peery M; Poklepovic A; Dent P
Cancer Biol Ther; 2014; 15(12):1646-57. PubMed ID: 25482938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
